Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 21, Issue 12, 1998, Pages 1267-1269

  Picardi, M ^a   Selleri, C ^a   De Rosa, G ^a   Raiola, A ^a   Pezzullo, L ^a   Rotoli, B ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Divisione di Ematologia   (Italy)

Author keywords

Bone marrow transplantation; Chronic hepatitis B virus infection; Lamivudine

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; VIRUS DNA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER INJURY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; VIRUS REPLICATION;

EID: 0031872819     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701266     Document Type: Article

References (10)

1. Locasciulli A, Alberti A, Bandini G et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995; 86: 3236-3240.
2. Locasciulli A, Alberti A, de Bock R et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious Diseases Working Party. Bone Marrow Transplant 1994; 14: 833-837.
3. Locasciulli A. Hepatitis viruses infections in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 115-116.
4. Wong DKH, Cheung AM, O' Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med 1993; 119: 312-323.
5. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New Engl J Med 1990; 323: 2295-2301.
6. Miura J, Takamatsu H, Okumura H et al. Allogeneic bone marrow transplantation for a patient complicated by chronic hepatitis due to precore mutant hepatitis B virus: failure of management with interferon-α therapy. Am J Hematol 1997; 54: 344-345.
7. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroeterology 1997; 113: 1258-1263.
8. Dienstag LJ, Perrillo RP, Schiff ER et al. A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl J Med 1995; 333: 1657-1661.
9. Chen PM, Fan S, Liu Ch et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-713.
10. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.